Michael K.K. Wong, MD, PhD, on KRT-232: First-in-Class Agent for Merkel Cell Carcinoma
Posted: Wednesday, June 24, 2020
Michael K.K. Wong, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a possible new treatment for patients with Merkel cell carcinoma: the MDM2 inhibitor KRT-232. It demonstrated monotherapy activity in p53 wild-type disease that did not respond to anti–PD-1/PD-L1 treatment.